Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mako misses predicted price range with IPO

This article was originally published in Clinica

Executive Summary

Mako Surgical, a manufacturer of minimally-invasive knee implants, has launched on the Nasdaq Stock Exchange at a lesser price than it had originally expected. Mako debuted on the Nasdaq at $10 per share on February 13, a considerable mark-down from the original $14-16 price range it had set the offering at in an SEC filing in September last year (see Clinica No 1275, p 15). With the lowered IPO pricing, the Fort Lauderdale, Florida-based company expects to net $47.1m in proceeds, compared to the previously anticipated $68.4m. It said it expects to use approximately $14-20m on the expansion of its sales and marketing activities, around $12-18m on R&D and a $4m payment to IBM, a requirement of the IPO under the terms of a licensing agreement between the two firms. By the end of its first week of trading, Mako shares had dropped by 3% to $9.72 per share. The company produces Makoplasty technology to help surgeons treat patient-specific, early- to mid-stage osteoarthritic knee disease.

You may also be interested in...



Connected Strategies Are Vital For Medtechs In The Consumer-Led 2020s

Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.

ESG In 2020: Not A Tick-Box Exercise But A Strategic Opportunity

The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.

Polish Industry Fighting Against Advertising Tax On Supplements

Advertising dietary supplements in Poland will incur a new tax under proposals from the country's Ministry of Health. While the government claims the motivation is to promote healthy eating choices, industry says supplements have been unfairly linked to poor dietary choices without evidence.

Topics

UsernamePublicRestriction

Register

MT046151

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel